NEW YORK (GenomeWeb) – Protea Biosciences has licensed a mass spectrometry-based technology from Yale University aimed at improving diagnosis of melanoma.

The Morgantown, West Virginia-based firm is developing a test that will use proteomic mass spec imaging (MSI), pioneered by Yale Dermatology Professor Rossitza Lazova and Protea's Erin Seeley.

According to the partners, the imaging technology allows researchers to identify hundreds of specific proteins in tissue, which can help distinguish between cancerous melanomas and benign moles, also called melanocytic nevi.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.

A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.

Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.

In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.